Go offline with the Player FM app!
First to Market: Unlocking Switzerland’s Pharma Potential
Manage episode 519077319 series 3381584
What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?
This episode explores Switzerland’s potential as an early launch market.
In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.
Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.
We discussed:
- What makes Switzerland attractive as a first-launch market
- Key differences between Swiss and European Union (EU) market access pathways
- How to prepare for inclusion on the SL and what “economically efficient pricing” really means
- The role of cantonal (state) variation and decentralised healthcare in shaping access
- How Swiss decisions may be influenced by the EU’s JCA
- What global teams can learn from Swiss strategy to inform broader launch planning
This episode was first broadcast as a live webinar on Thursday 16th October 2025
Learn more at https://petauri.com/insights/market-access-switzerland/
Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence
Chapters
1. Intro & Topic Overview (00:00:00)
2. Guest Introduction: Elisabeth Brock (00:01:29)
3. Overview of the Swiss Healthcare System (00:03:13)
4. Role of Cantons in Healthcare Planning & Financing (00:04:52)
5. Compulsory Health Insurance: How It Works (00:07:26)
6. Supplementary Private Insurance in Switzerland (00:09:08)
7. Role of the Federal Office of Public Health (FOPH) (00:10:02)
8. Role of Swiss Medic: The Regulator (00:10:45)
9. Similarities & Differences with Other European Markets (00:12:38)
10. Opportunities for Launching First in Switzerland (00:14:20)
11. Challenges for Launching First in Switzerland (00:18:58)
12. Main Routes to Reimbursement (00:20:35)
13. What Manufacturers Need to Prepare for Reimbursement (00:22:18)
14. Economic Efficiency & Price Calculation Explained (00:25:24)
15. Evidence Requirements for Swiss Dossiers (00:28:03)
16. Importance of Local Insight & KOL Engagement (00:32:56)
17. Routes for Diagnostics & Devices (00:36:45)
18. Upcoming Changes & EFAS Reform (00:38:48)
19. Swiss Openness to Confidential Discounts (00:41:49)
20. Closing Remarks & Wrap-Up (00:43:40)
71 episodes
Manage episode 519077319 series 3381584
What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?
This episode explores Switzerland’s potential as an early launch market.
In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.
Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.
We discussed:
- What makes Switzerland attractive as a first-launch market
- Key differences between Swiss and European Union (EU) market access pathways
- How to prepare for inclusion on the SL and what “economically efficient pricing” really means
- The role of cantonal (state) variation and decentralised healthcare in shaping access
- How Swiss decisions may be influenced by the EU’s JCA
- What global teams can learn from Swiss strategy to inform broader launch planning
This episode was first broadcast as a live webinar on Thursday 16th October 2025
Learn more at https://petauri.com/insights/market-access-switzerland/
Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence
Chapters
1. Intro & Topic Overview (00:00:00)
2. Guest Introduction: Elisabeth Brock (00:01:29)
3. Overview of the Swiss Healthcare System (00:03:13)
4. Role of Cantons in Healthcare Planning & Financing (00:04:52)
5. Compulsory Health Insurance: How It Works (00:07:26)
6. Supplementary Private Insurance in Switzerland (00:09:08)
7. Role of the Federal Office of Public Health (FOPH) (00:10:02)
8. Role of Swiss Medic: The Regulator (00:10:45)
9. Similarities & Differences with Other European Markets (00:12:38)
10. Opportunities for Launching First in Switzerland (00:14:20)
11. Challenges for Launching First in Switzerland (00:18:58)
12. Main Routes to Reimbursement (00:20:35)
13. What Manufacturers Need to Prepare for Reimbursement (00:22:18)
14. Economic Efficiency & Price Calculation Explained (00:25:24)
15. Evidence Requirements for Swiss Dossiers (00:28:03)
16. Importance of Local Insight & KOL Engagement (00:32:56)
17. Routes for Diagnostics & Devices (00:36:45)
18. Upcoming Changes & EFAS Reform (00:38:48)
19. Swiss Openness to Confidential Discounts (00:41:49)
20. Closing Remarks & Wrap-Up (00:43:40)
71 episodes
Alle episoder
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.